Impax Laboratories Inc. (IPXL)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.70+0.11 (+0.47%)
At close: 4:00 PM EDT
People also watch:
MDCOLCIENDPAKRXDEPO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open23.59
Prev Close23.59
Bid22.25 x 200
Ask30.00 x 100
Day's Range23.30 - 24.22
52wk Range20.97 - 45.00
1y Target EstN/A
Market Cap1.75B
P/E Ratio (ttm)50.21
Beta1.40
Volume842,321
Avg Vol (3m)985,914
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Impax Laboratories, Inc. – Value Analysis (NASDAQ:IPXL) : September 28, 2016
    Capital Cube2 days ago

    Impax Laboratories, Inc. – Value Analysis (NASDAQ:IPXL) : September 28, 2016

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Impax Laboratories, Inc. a score of 56. Our analysis is based on comparing Impax Laboratories, Inc. with the following peers – Mylan N.V., Lannett Company, Inc., Pfizer Inc., Shire PLC Sponsored ADR, Valeant Pharmaceuticals International Inc, Endo International Plc, Astrazeneca PLC Sponsored ADR and Teva Pharmaceutical Industries ... Read more (Read more...)

  • Impax Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IPXL-US : September 27, 2016
    Capital Cube3 days ago

    Impax Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IPXL-US : September 27, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Impax Laboratories, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • PR Newswire8 days ago

    Impax Launches Generic Version of Metadate CD® (Methylphenidate Hydrochloride Extended-Release Capsules)

    Impax is focused on further enhancing its portfolio of 73 solid oral dose and alternative dosage form generic products available. The launch of methylphenidate hydrochloride is Impax's sixth new product launch since the beginning of 2016. Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products.